Quarterly report pursuant to Section 13 or 15(d)

Consolidated Statements of Operations

v2.4.0.8
Consolidated Statements of Operations (USD $)
In Thousands, except Share data, unless otherwise specified
3 Months Ended 6 Months Ended 84 Months Ended
Jun. 30, 2013
Jun. 30, 2012
Jun. 30, 2013
Jun. 30, 2012
Jun. 30, 2013
Operating expenses:          
Research and development $ 7,795 $ 4,525 $ 13,769 $ 9,116 $ 55,778
General and administrative 2,499 1,940 4,983 3,930 21,262
In-process research and development         21,749
Loss from operations (10,294) (6,465) (18,752) (13,046) (98,789)
Interest income 109 29 185 73 665
Interest expense (485) (19) (961) (38) (4,914)
Other income         733
Warrant expense         (1,407)
Net loss (10,670) (6,455) (19,528) (13,011) (103,712)
Common Stock dividend to Series A Convertible Preferred Stockholders         (5,861)
Net loss attributed to Common Stock $ (10,670) $ (6,455) $ (19,528) $ (13,011) $ (109,573)
Basic and diluted net loss per common share $ (0.38) $ (0.34) $ (0.73) $ (0.69)  
Weighted average common shares outstanding - basic and diluted 28,095,522 19,194,053 26,646,993 18,899,149